New combo therapy shows promise for Hard-to-Treat lung cancer
NCT ID NCT06525246
First seen Mar 19, 2026 · Last updated Jun 18, 2026 · Updated 6 times
Summary
This early-phase study tested a new drug called ONO-7475 combined with the standard targeted therapy osimertinib in 78 people with advanced EGFR-mutated non-small cell lung cancer. The goal was to see if the combination is safe and tolerable. Participants had stage IIIB, IIIC, IV, or recurrent lung cancer not suitable for radiation. The study measured side effects, drug levels in the body, and how well the cancer responded.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hyogo College Of Medicine College Hospital
Nishinomiya, Hyōgo, Japan
-
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
-
Kitasato University Hospital
Sagamihara-shi, Kanagawa, Japan
-
Kobe City Medical Center General Hospital
Kobe, Hyōgo, Japan
-
National Hospital Organization Shikoku Cancer Center
Matsuyama, Ehime, Japan
-
Nigata Cancer Center Hospital
Niigata, Niigata, Japan
-
Osaka International Cancer Institute
Osaka, Osaka, Japan
-
Osaka Medical and Pharmaceutical University Hospital
Takatsuki, Osaka, Japan
-
Saitama Cancer Center
Ina, Kitaadati-gun, Saitama, Japan
-
Shizuoka Cancer Center
Nagaizumi-chō, Sunto-gun, Shizuoka, Japan
-
The Cancer Institute Hospital Of JFCR
Koto-Ku, Tokyo, Japan
-
Tokyo Medical University Hospital
Shinjuku-Ku, Tokyo, Japan
-
University Hospital Kyoto Prefectural University of Medicine
Kyoto, Kyoto, Japan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.